| 摘要 |
Disclosed is a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. Also disclosed are polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment. Such polynucleotides and polypeptides are useful in the treatment of conditions such as cancer including renal carcinoma and malignant melanoma, HIV, autoimmune diseases, infectious diseases, immune deficiency including SCID, and in other therapeutic applications requiring stimulation of the immune system.
|
